Literature DB >> 32664839

The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.

Elmira Mohtashami1, Negar Shafaei-Bajestani2, Hamid Mollazadeh3,4, Seyed Hadi Mousavi5, Mohammad Jalili-Nik6, Amirhossein Sahebkar7,8,9,10, Amir R Afshari3.   

Abstract

Glioblastoma multiforme (GBM), as the most lethal brain tumor, continues to be incurable. Considering the high mortality rate of GBM, it is crucial to develop new treatment approaches. Conventional therapies, including maximal surgical resection, radiation therapy, and chemotherapy (typically temozolomide), have not led to significant changes in the survival rates of GBM patients. However, emerging modalities, such as the use of tyrosine kinase inhibitors, mTOR inhibitors, NF-κB modulators, nitrosoureas, and immunotherapeutic agents have shown promising in improving GBM outcomes. In this context, we reviewed the current status of GBM treatment, the efficacy of existing standard therapies in improving disease outcomes, and future therapeutic directions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Glioblastoma multiforme; NF-κB modulator; immunotherapy; mTOR inhibitor; nitrosoureas; tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2020        PMID: 32664839     DOI: 10.2174/1389200221666200714101038

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  5 in total

1.  Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma.

Authors:  Nikhil Rammohan; Alexander Ho; Mohit Saxena; Amishi Bajaj; Tim J Kruser; Craig Horbinski; Alexander Korutz; Matthew Tate; Sean Sachdev
Journal:  J Neurooncol       Date:  2022-05-07       Impact factor: 4.130

Review 2.  How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme.

Authors:  Mehdi Sanati; Samaneh Aminyavari; Hamid Mollazadeh; Bahram Bibak; Elmira Mohtashami; Amir R Afshari
Journal:  Pharmacol Rep       Date:  2022-01-20       Impact factor: 3.024

3.  Treatment approach and survival from glioblastoma: results from a population-based retrospective cohort study from Western Norway.

Authors:  Line Sagerup Bjorland; Oystein Fluge; Bjornar Gilje; Rupavathana Mahesparan; Elisabeth Farbu
Journal:  BMJ Open       Date:  2021-03-12       Impact factor: 2.692

4.  Chemotherapy-Induced Degradation of Glycosylated Components of the Brain Extracellular Matrix Promotes Glioblastoma Relapse Development in an Animal Model.

Authors:  Alexandra Y Tsidulko; Oleg B Shevelev; Anna S Khotskina; Mariia A Kolpakova; Anastasia V Suhovskih; Galina M Kazanskaya; Alexander M Volkov; Svetlana V Aidagulova; Evgenii L Zavyalov; Elvira V Grigorieva
Journal:  Front Oncol       Date:  2021-07-19       Impact factor: 6.244

5.  LncRNA FOXD3-AS1 Promotes Tumorigenesis of Glioma via Targeting miR-128-3p/SZRD1 Axis.

Authors:  Zhang Li; Ming Li; Pengcheng Xia; Lili Wang; Zhiming Lu
Journal:  Cancer Manag Res       Date:  2021-12-07       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.